Lonza to Host New Webinar – "3D Cell Culture Models for Respiratory Research"
Basel, Switzerland, 22 April 2020 – On 6 May Lonza will host a free 60-minute webinar on the importance of using advanced three-dimensional (3D) cell culture models that closely mimic lung diseases like COVID-19, to streamline and optimize respiratory research.
With the world battling the devastating COVID-19 pandemic, drug discovery researchers are under enormous pressure to deliver a safe and effective treatment. 3D cell culture is increasingly becoming the preferred in vitro approach for studying lung cell biology, as it provides more physiologically relevant and predictive data for in vivo testing. However, conventional 3D cell culture technology has been associated with time and process optimization challenges, which can have a negative impact on experimental efficiency and timelines. Lonza’s RAFT™ 3D Cell Culture System offers a complete solution designed to simplify and accelerate the development of complex in vitro models for advanced respiratory research.
In the webinar titled "3D Cell Culture Models for Respiratory Research", Dr Davide Confalonieri, Channel Manager, Sales EU at Lonza, will discuss the following topics:
- Modeling the airway: 2D vs 3D cell culture
- Development of a multilayered 3D bronchial epithelium for disease modeling and toxicity testing
- 3D airway model configurations enabled using the RAFT™ 3D Cell Culture System
- The benefits of air-liquid interface cultures
- Case studies to demonstrate the benefits of 3D respiratory cell culture models
More information about attending the webinar is available here.
3D Cell Culture Models for Respiratory Research
Speaker: Davide Confalonieri
6 May 2020
- 8 AM PDT (Los Angeles)
- 11 AM EDT (New York)
- 4 PM BST (London)
- 5 PM CEST (Berlin)
Further information can be found on the RAFT™ 3D Cell Culture System web page. By registering interest in the webinar, participants will also receive a link once it is available to view the webinar "on demand" via the Lonza website.
More information about Lonza’s upcoming and on-demand webinars is available here: www.lonza.com/webinars
Lonza is an integrated solutions provider that creates value along the Healthcare Continuum®. Through our Pharma Biotech & Nutrition segment and our Specialty Ingredients segment businesses, we harness science and technology to serve markets along this continuum. We focus on creating a healthy environment, promoting a healthier lifestyle and preventing illness through consumers' preventive healthcare, as well as improving patient healthcare by supporting our customers to deliver innovative medicines that help treat or even cure severe diseases.
Patients and consumers benefit from our ability to transfer our pharma know-how to the healthcare, hygiene and fast-moving consumer goods environment and to the preservation and protection of the world where we live.
Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 15,500 full-time employees worldwide at the end of 2018. The company generated sales of CHF 5.5 billion in 2018 with a CORE EBITDA of CHF 1.5 billion. Further information can be found at www.lonza.com.
Media Contact Details:
Aimi Papanastasiou (BSc, MA)
Tel: +44 (0)1223 627136
Additional Information and Disclaimer
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.
Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.